Abbott Receives CE Mark for World's First Dual Glucose-Ketone Sensor for Diabetes

Abbott has achieved CE marking for the world's first dual glucose-ketone sensing technology. This new technology enables diabetes patients to monitor their blood sugar and ketone levels simultaneously. The CE mark signifies that the product can be marketed within the European Economic Area. The company emphasizes that this innovation represents a significant step in diabetes management. Monitoring ketone levels plays a critical role in reducing the risk of ketoacidosis, particularly in patients with type 1 diabetes. Abbott's technology aims to simplify treatment by allowing patients to track two important biomarkers with a single sensor. Abbott is known for its continuous innovations in the diabetes field. The company had previously established a strong market presence with its glucose monitoring systems. The new dual-sensor technology is expected to offer an accessible and convenient solution for diabetes patients, especially in Europe. This development is seen as part of Abbott's strategy to expand its medical technology portfolio. With the CE mark, the company gains the right to market the product in Europe, while continuing regulatory approval processes in other regions. This is not investment advice.